Literature DB >> 17682100

Health care-associated pneumonia and community-acquired pneumonia: a single-center experience.

Scott T Micek1, Katherine E Kollef, Richard M Reichley, Nareg Roubinian, Marin H Kollef.   

Abstract

Pneumonia occurring outside of the hospital setting has traditionally been categorized as community-acquired pneumonia (CAP). However, when pneumonia is associated with health care risk factors (prior hospitalization, dialysis, residing in a nursing home, immunocompromised state), it is now more appropriately classified as a health care-associated pneumonia (HCAP). The relative incidences of CAP and HCAP among patients requiring hospital admission is not well described. The objective of this retrospective cohort study, involving 639 patients with culture-positive CAP and HCAP admitted between 1 January 2003 and 31 December 2005, was to characterize the incidences, microbiology, and treatment patterns for CAP and HCAP among patients requiring hospital admission. HCAP was more common than CAP (67.4% versus 32.6%). The most common pathogens identified overall included methicillin-resistant Staphylococcus aureus (24.6%), Streptococcus pneumoniae (20.3%), Pseudomonas aeruginosa (18.8%), methicillin-sensitive Staphylococcus aureus (13.8%), and Haemophilus influenzae (8.5%). The hospital mortality rate was statistically greater among patients with HCAP than among those with CAP (24.6% versus 9.1%; P < 0.001). Administration of inappropriate initial antimicrobial treatment was statistically more common among HCAP patients (28.3% versus 13.0%; P < 0.001) and was identified as an independent risk factor for hospital mortality. Our study found that the incidence of HCAP was greater than that of CAP among patients with culture-positive pneumonia requiring hospitalization at Barnes-Jewish Hospital. Patients with HCAP were more likely to initially receive inappropriate antimicrobial treatment and had a greater risk of hospital mortality. Health care providers should differentiate patients with HCAP from those with CAP in order to provide more appropriate initial antimicrobial therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17682100      PMCID: PMC2043297          DOI: 10.1128/AAC.00851-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  18 in total

1.  Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2005-02-15       Impact factor: 21.405

2.  Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock.

Authors:  Anand Kumar; Daniel Roberts; Kenneth E Wood; Bruce Light; Joseph E Parrillo; Satendra Sharma; Robert Suppes; Daniel Feinstein; Sergio Zanotti; Leo Taiberg; David Gurka; Aseem Kumar; Mary Cheang
Journal:  Crit Care Med       Date:  2006-06       Impact factor: 7.598

3.  The value of routine microbial investigation in ventilator-associated pneumonia.

Authors:  J Rello; M Gallego; D Mariscal; R Soñora; J Valles
Journal:  Am J Respir Crit Care Med       Date:  1997-07       Impact factor: 21.405

4.  Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment.

Authors:  Scott T Micek; Ann E Lloyd; David J Ritchie; Richard M Reichley; Victoria J Fraser; Marin H Kollef
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

5.  The influence of mini-BAL cultures on patient outcomes: implications for the antibiotic management of ventilator-associated pneumonia.

Authors:  M H Kollef; S Ward
Journal:  Chest       Date:  1998-02       Impact factor: 9.410

6.  Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia.

Authors:  Marin H Kollef; Andrew Shorr; Ying P Tabak; Vikas Gupta; Larry Z Liu; R S Johannes
Journal:  Chest       Date:  2005-12       Impact factor: 9.410

7.  Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia.

Authors:  C M Luna; P Vujacich; M S Niederman; C Vay; C Gherardi; J Matera; E C Jolly
Journal:  Chest       Date:  1997-03       Impact factor: 9.410

8.  Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients.

Authors:  M H Kollef; G Sherman; S Ward; V J Fraser
Journal:  Chest       Date:  1999-02       Impact factor: 9.410

9.  Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis.

Authors:  Stephan Harbarth; Jorge Garbino; Jérome Pugin; Jacques A Romand; Daniel Lew; Didier Pittet
Journal:  Am J Med       Date:  2003-11       Impact factor: 4.965

10.  Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis.

Authors:  Jose Garnacho-Montero; Jose Luis Garcia-Garmendia; Ana Barrero-Almodovar; Francisco J Jimenez-Jimenez; Carmen Perez-Paredes; Carlos Ortiz-Leyba
Journal:  Crit Care Med       Date:  2003-12       Impact factor: 7.598

View more
  100 in total

1.  Guidelines for the management of adult lower respiratory tract infections--full version.

Authors:  M Woodhead; F Blasi; S Ewig; J Garau; G Huchon; M Ieven; A Ortqvist; T Schaberg; A Torres; G van der Heijden; R Read; T J M Verheij
Journal:  Clin Microbiol Infect       Date:  2011-11       Impact factor: 8.067

Review 2.  Advances in the management of sepsis and the understanding of key immunologic defects.

Authors:  Lee P Skrupky; Paul W Kerby; Richard S Hotchkiss
Journal:  Anesthesiology       Date:  2011-12       Impact factor: 7.892

3.  Predictive value of methicillin-resistant Staphylococcus aureus (MRSA) nasal swab PCR assay for MRSA pneumonia.

Authors:  Benjamin Dangerfield; Andrew Chung; Brandon Webb; Maria Teresa Seville
Journal:  Antimicrob Agents Chemother       Date:  2013-11-25       Impact factor: 5.191

4.  Epidemiology and predictors of multidrug-resistant community-acquired and health care-associated pneumonia.

Authors:  Alan E Gross; Trevor C Van Schooneveld; Keith M Olsen; Mark E Rupp; Thu Hong Bui; Elsie Forsung; Andre C Kalil
Journal:  Antimicrob Agents Chemother       Date:  2014-06-23       Impact factor: 5.191

5.  Performance of PSI, CURB-65, and SCAP scores in predicting the outcome of patients with community-acquired and healthcare-associated pneumonia.

Authors:  Marco Falcone; Salvatore Corrao; Mario Venditti; Pietro Serra; Giuseppe Licata
Journal:  Intern Emerg Med       Date:  2011-01-20       Impact factor: 3.397

6.  Emerging problems regarding severity assessment and treatment strategies for patients with pneumonia: controversies surrounding the HCAP concept.

Authors:  Yuichiro Shindo; Yoshinori Hasegawa
Journal:  Intern Emerg Med       Date:  2011-05-18       Impact factor: 3.397

7.  Evolution of Pseudomonas aeruginosa type III secretion in cystic fibrosis: a paradigm of chronic infection.

Authors:  Manu Jain; Maskit Bar-Meir; Susanna McColley; Joanne Cullina; Eileen Potter; Cathy Powers; Michelle Prickett; Roopa Seshadri; Borko Jovanovic; Argyri Petrocheilou; John D King; Alan R Hauser
Journal:  Transl Res       Date:  2008-10-31       Impact factor: 7.012

8.  Disparities of care for African-Americans and Caucasians with community-acquired pneumonia: a retrospective cohort study.

Authors:  Christopher R Frei; Eric M Mortensen; Laurel A Copeland; Russell T Attridge; Mary Jo V Pugh; Marcos I Restrepo; Antonio Anzueto; Brandy Nakashima; Michael J Fine
Journal:  BMC Health Serv Res       Date:  2010-05-27       Impact factor: 2.655

Review 9.  Imipenem resistance of Pseudomonas in pneumonia: a systematic literature review.

Authors:  Marya D Zilberberg; Joyce Chen; Samir H Mody; Andrew M Ramsey; Andrew F Shorr
Journal:  BMC Pulm Med       Date:  2010-08-26       Impact factor: 3.317

10.  New perspectives on community-acquired pneumonia in 388 406 patients. Results from a nationwide mandatory performance measurement programme in healthcare quality.

Authors:  S Ewig; N Birkner; R Strauss; E Schaefer; J Pauletzki; H Bischoff; P Schraeder; T Welte; G Hoeffken
Journal:  Thorax       Date:  2009-05-18       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.